Novartis Signs a License Agreement with Mesoblast to Develop and Commercialize Remestemcel-L for ARDS
Shots:
- Mesoblast to receive $25M up front and $25M as equity investment with additional payments and royalties on achievement of development- regulatory and commercial milestones
- Novartis to acquire the exclusive WW rights to develop- commercialize & manufacture remestemcel-L for ARDS & access to a cell-therapy based platform with WW rights to a range of potential indications. Novartis has the option to distribute remestemcel-L for GVHD (outside Japan)
- Both parties have rights to co-fund development & commercialization for other non-respiratory indications. Remestemcel-L is currently being studied in COVID-19-related ARDS in an ongoing P-III study while Novartis plans to initiate a P-III study in non-COVID-19-related ARDS
Ref: Novartis | Image: Novartis
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com